Female pattern hair loss is hormonal too — just different hormones.
For women, pattern hair loss is driven by androgens (testosterone and DHT) binding to sensitive scalp follicles, causing them to miniaturize over time. The trigger is often a shift in hormone balance — perimenopause, postpartum, PCOS, or simply genetic susceptibility — that makes follicles more reactive to the androgens already in your body.
Spironolactone blocks androgen receptors at the follicle, preventing testosterone and DHT from binding and shrinking the hair. Minoxidil increases follicular blood flow and prolongs the growth phase of the hair cycle. Together, they address both the hormonal driver and the follicular response.
Minoxidil + Spironolactone
Female pattern hair loss, by the numbers.
Both minoxidil and spironolactone are well-established in clinical practice for female pattern hair loss, with decades of off-label use and growing trial data.
Individual results vary. Spironolactone and low-dose oral minoxidil are both used off-label for female pattern hair loss in the United States. Compounded combination tablets are prepared by a licensed compounding pharmacy and are not FDA-approved as finished drug products. Sinclair 2005 used 200mg/day spironolactone; this compounded combination uses 60mg, which sits at the low end of the clinical dose range (25–200mg, mean ~100mg in published series) — your provider may adjust at follow-up. Results are not guaranteed.
Two complementary mechanisms in one daily tablet.
Spironolactone — Androgen Receptor Blockade
Spironolactone competitively blocks androgen receptors at the hair follicle. Even with normal androgen levels, sensitive follicles miniaturize when androgens bind. By occupying the receptor, spironolactone reduces follicular sensitivity to testosterone and DHT — addressing the root hormonal driver of female pattern loss. (Spironolactone is also a potassium-sparing diuretic, originally developed for blood pressure and edema; the anti-androgen effect is what we use here.)
Minoxidil — Follicular Vasodilation
Minoxidil is a potassium channel opener that dilates the small blood vessels feeding hair follicles. Better blood flow means better oxygen and nutrient delivery to the hair bulb. It also extends the anagen (active growth) phase of the hair cycle, giving each hair more time to grow before shedding. Low-dose oral minoxidil (1mg here) achieves these effects with fewer scalp-irritation side effects than topical formulations.
Prescribed for
What to expect month by month.
Months 1–3
Spironolactone starts blocking androgen receptors immediately. Minoxidil begins extending the growth phase. Some women experience a temporary increase in shedding in weeks 2–6 as the hair cycle synchronizes — this is normal and usually resolves. Do not stop treatment during this phase.
Months 3–6
Shedding phase resolves. Hair density begins to stabilize. The first signs of new growth — finer hairs along the part or thinning area — become visible. Energy and scalp sensitivity typically improve. Your provider may check blood pressure and potassium during this window.
Months 6–9
Visible density improvement. New hairs are thicker and longer than the miniaturized hairs they replaced. Many women report noticeable improvement in part width or coverage at the crown. Best estimate window for the most patient-reported satisfaction.
Month 12+
Full response achieved in most responders. Continued daily use maintains results. Like all hair loss treatments, stopping leads to gradual loss of benefit as androgen receptors re-engage and minoxidil's growth-phase support stops. Long-term use is the norm.
Safety and what to monitor.
Spironolactone is a well-established medication with decades of clinical use. Both drugs in this tablet have known monitoring needs your provider will manage with you.
⚠ Important Safety Information
Pregnancy: Spironolactone is contraindicated in pregnancy — it can cause feminization of male fetuses. Women of childbearing potential must use reliable contraception while on this medication, and should stop immediately if pregnancy is possible. Potassium: Spironolactone is a potassium-sparing diuretic. Your provider will check baseline potassium and recheck periodically. Avoid potassium supplements and salt substitutes containing potassium unless your provider directs otherwise. Blood pressure: Both spironolactone and minoxidil can lower blood pressure; mild dizziness is possible, particularly in the first weeks. Drug interactions: ACE inhibitors, ARBs, NSAIDs, and lithium can interact with spironolactone — disclose all medications during intake. Kidney function: Disclose any history of kidney disease; baseline kidney function will be checked.
Common, usually mild side effects: Breast tenderness or fullness (more common at higher spironolactone doses; usually mild at 60mg), menstrual irregularities (lighter, missed, or shifted cycles), mild diuretic effect (increased urination, particularly in the first weeks), mild fluid retention from minoxidil, possible mild increase in body hair (hypertrichosis) from minoxidil — usually subtle at 1mg.
Less common: Headache, dizziness when standing quickly, mild fatigue.
Rare but report immediately: Persistent palpitations, severe dizziness, significant swelling, signs of high potassium (muscle weakness, irregular heartbeat).
Frequently asked question
Why this combination instead of just minoxidil or just spironolactone?
Female pattern hair loss has two drivers — hormonal sensitivity (androgens binding the follicle) and reduced growth-phase support (poor follicular blood flow, shortened anagen). Minoxidil addresses the second; spironolactone addresses the first. Used alone, each helps a subset of women. Used together, they cover both mechanisms — and clinical practice supports the combination for patients who plateau on single-active regimens.
Is 60mg of spironolactone enough?
Spironolactone for hair loss is dosed 25–200mg daily across published studies, with the typical mean around 80–110mg. 60mg sits in the low end of that window — intentionally, to balance meaningful anti-androgen effect against side effects (breast tenderness, blood pressure changes, electrolyte shifts). Lower doses also have less evidence for hair-specific outcomes but a more favorable side-effect profile. Your provider can adjust at follow-up if the response at 60mg is modest.
Can I take this if I might want to get pregnant?
No. Spironolactone is contraindicated in pregnancy because it can cause feminization of male fetuses. Women of childbearing potential must use reliable contraception while on the medication. If you are actively trying to conceive or pregnancy is possible, this formulation is not appropriate and you should discuss alternatives (such as topical-only options) with your provider.
Will my potassium need monitoring?
Yes — your provider will check baseline potassium before starting and recheck periodically. Spironolactone is a potassium-sparing diuretic, meaning it can raise serum potassium. The risk is higher in people with kidney disease or those on ACE inhibitors, ARBs, NSAIDs, or potassium supplements. Disclose all medications and any kidney history during intake. Most patients tolerate the medication without issue, but monitoring is part of safe long-term use.
How long before I see results?
Hair growth is slow. Expect the first 4–8 weeks to feature a brief synchronized shedding phase (normal, do not stop). Stabilization of further loss is typical by month 3. Visible regrowth is usually noticeable by month 6, with the most pronounced improvement between months 6–12. The full response typically takes 12 months of consistent daily use. If you don’t see improvement by month 6, talk to your provider about adjusting the protocol.
Is this a lifelong commitment?
For sustained results, yes. The underlying biology of female pattern hair loss continues regardless of treatment. If you stop, the gains are gradually lost as androgen receptors re-engage and the minoxidil-supported growth phase shortens. Many women view daily oral hair-loss medication as a long-term investment in hair preservation — the routine becomes simple after the first few weeks.
I'm postmenopausal — what's the right choice for me?
Postmenopausal women have more options. This Min/Spiro combination remains a strong choice and avoids the teratogenicity concerns that constrain younger women. However, postmenopausal women can also be prescribed finasteride or other 5α-reductase inhibitors off-label — different mechanism, different side-effect profile, no androgen-receptor blockade. The right choice depends on your goals, tolerance for systemic anti-androgen effects (breast tenderness, blood pressure), and whether you have a strong family history of male pattern loss. Your provider will discuss both paths during intake. See also the Oral Hair Loss page for finasteride-based options.
Important: Minoxidil 1mg / Spironolactone 60mg is a compounded prescription product prepared by a licensed compounding pharmacy. Both active ingredients are FDA-approved for other indications (minoxidil for hypertension; spironolactone for hypertension, heart failure, edema, and hyperaldosteronism). Use for female pattern hair loss is off-label and is prescribed at provider discretion following clinical review. Spironolactone is contraindicated in pregnancy. Women of childbearing potential must use reliable contraception while on this medication. Compounded combination tablets are not FDA-approved as finished drug products. Individual results vary; not all patients respond. Prescription required. All Obsidian Genetics prescriptions are issued following clinical review by a licensed provider. © 2026 Obsidian Genetics. All rights reserved.